Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether ARA 290, a new class of compound, is
effective in the treatment of the neuropathic symptoms of sarcoidosis. Brief interaction of
ARA 290 with the innate repair receptor results in anti-apoptotic and anti-inflammatory
activities in myriad of cells, tissues and organs throughout the body to activate repair
mechanisms and accelerate healing, including the nerve damage that can be associated with
sarcoidosis. In this study, subjects with sarcoidosis and symptoms of small fiber neuropathy
will administered ARA 290 or placebo by subcutaneous injection daily for 28 days. In addition
to monitoring the safety of the treatment, the symptoms of the subjects will be assessed with
several questionnaires, function tests, and measurement of nerve fibers in their cornea and
skin (via a non-invasive test and a biopsy, respectively). The total participation time for
each patient will be 16 weeks.